Anticancer Therapy SMRT-ens Up: Targeting the BCL6-SMRT Interaction in B Cell Lymphoma

Cancer Cell

Volumn 17, Issue 4, 2010, Pages 315-316

  Compton, Leigh A ^a   Hiebert, Scott W ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; HISTONE DEACETYLASE INHIBITOR; PREDNISONE; PROTEIN BCL 6; PROTEIN INHIBITOR; PROTEIN INHIBITOR 79 6; RITUXIMAB; SILENCING MEDIATOR OF RETINOID AND THYROID HORMONE RECEPTOR; UNCLASSIFIED DRUG; VINCRISTINE;

ADD ON THERAPY; B CELL LYMPHOMA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN INTERACTION; SHORT SURVEY; UNSPECIFIED SIDE EFFECT;

EID: 77950514654     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2010.03.012     Document Type: Short Survey

References (8)

1. Arkin M.R., and Wells J.A. Nat. Rev. Drug Discov. 3 (2004) 301-317
2. Arkin M.R., and Whitty A. Curr. Opin. Chem. Biol. 13 (2009) 284-290
3. Cerchietti L.C., Ghetu A.F., Zhu X., Da Silva G.F., Zhong S., Matthews M., Bunting K.L., Polo J.M., Farès C., Arrowsmith C.H., et al. Cancer Cell 17 (2010) 400-411 this issue
4. Jardin F., Ruminy P., Bastard C., and Tilly H. Pathol. Biol. (Paris) 55 (2007) 73-83
5. Kahl B. Semin. Hematol. 45 (2008) 90-94
6. Lossos I.S. J. Clin. Oncol. 23 (2005) 6351-6357
7. Parekh S., Prive G., and Melnick A. Leuk. Lymphoma 49 (2008) 874-882
8. Stimson L., Wood V., Khan O., Fotheringham S., and La Thangue N.B. Ann. Oncol. 20 (2009) 1293-1302